Optimal induction treatment regimens for extranodal NK/T-cell lymphoma: lessons learned, challenges, and proposals

• DOI: 10.31491/apt.2020.12.045
• Publication Date: 2020-12-31T07:34:15Z
• Authors: Jing Yang; Ruiying Fu; Xindi Liu; Liqiang Wei; Liang Wang
• Keywords: 0301 basic medicine; 03 medical and health sciences; 3. Good health

Extranodal NK/T-cell lymphoma (ENKTCL) is a highly aggressive and Epstein-Bar virus (EBV)-associated hematologic malignancy, most prevalent in the Far East and South America. No standard treatment strategy has been defined. It is well recognized that combination of asparaginase-based chemotherapy (CT) and radiotherapy (RT) benefit early-stage ENKTCL. It has been validated that upfront RT can cure most stage I patients of ENKTCL without risk factors, and asparaginase (either L-asparaginase or pegaspargase) is the backbone of chemotherapy for ENKTCL.